EQS-News: RHÖN-KLINIKUM AG continues stable trend in first half of 2026
|
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Half Year Results/Miscellaneous
CORPORATE NEWS RHÖN-KLINIKUM AG continues stable trend in first half of 2026
Bad Neustadt, 6 August 2026 – RHÖN-KLINIKUM AG reports another stable business performance in the first half of 2026. Consolidated revenue of EUR 863.6 million slightly exceeded the previous year’s level (H1 2025: EUR 833.5 million), and EBITDA was EUR 57.0 million (H1 2025: EUR 46.7 million). Consolidated profit totalled EUR 22.5 million (H1 2025: EUR 14.7 million). The sites are continuously evolving to expand and improve regional healthcare provision. In addition to the major investments in state-of-the-art medical technology planned for 2026 at all sites, medical and therapeutic care offerings are being further expanded and regional cooperation networks established. In Hesse, for example, Universitätsklinikum Marburg and the pulmonary clinic Lungenfachklinik Immenhausen are pooling their expertise. The purpose of this strategic partnership is to effectively promote the care of lung patients by working together. Parallel to these developments, the care network in Brandenburg is growing. With the newly opened child protection emergency service at the RHÖN-KLINIKUM Frankfurt (Oder) site, a strong regional network has been created. The newly signed cooperation agreements between the hospital, the City of Frankfurt (Oder) and the District of Oder-Spree ensure close, inter-institutional collaboration to seamlessly coordinate fast and effective help for affected children and adolescents. Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG: “Regional networks form a vital and essential part of any future healthcare system. Rigid sectoral boundaries make it more difficult to provide patients with the care they need and saddle our healthcare system with unnecessary costs. It is only when general practitioners, specialists, medical facilities, nurses and therapists work together as a team that we can pool our resources efficiently. In the face of mounting pressures, such collaboration across providers is the only way to ensure comprehensive and high-quality care to patients, especially in rural areas.” Dr. Stefan Stranz, member of the Board of Management of RHÖN-KLINIKUM AG: “The Statutory Health Insurance Contribution Rate Stabilization Act imposes further burdens on hospitals. Instead of reducing bureaucracy and refocusing on patient care, the reform saddles already overburdened hospitals with even more documentation requirements, excessive budget cuts, and financial risks.” Outlook for 2026 For the current financial year, we expect revenues of EUR 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between EUR 110 million and EUR 125 million. In addition to financial performance indicators, we also take account of the non-financial performance indicators of number of cases and cost weights in the management of the company and expect these to show a moderate improvement over the previous year. The financial year will be significantly impacted by the unfolding legislation process and the considerable uncertainties it holds. Particularly, the Hospital Reform Adjustment Act (Krankenhausreformanpassungsgesetz, KHAG) that entered into force on 15 April 2026 and the Statutory Health Insurance (SHI) Contribution Rate Stabilisation Act (GKV-Beitragsstabilisierungsgesetz, GKV-BstabG) (GKV-BStabG) adopted by the German Federal Parliament on 10 July 2026 seek to further enhance quality and efficiency in the healthcare system, but at the same time will put hospitals under greater financial pressure in the short term. The company’s forecast is therefore subject to particular uncertainties. It is not yet possible at this time to reliably forecast what overall impact the ongoing regulatory interference, the implementation of the hospital reform as well as further possible adjustments by the legislator will have. On top of that, the ongoing global crises and negative economic impacts are resulting among other things in higher prices, supply bottlenecks and general market volatility. This Interim Report – Report on the First Half of 2026 – is published on the Internet . CONTACT RHÖN-KLINIKUM AG | Head of Group Finance RHÖN-KLINIKUM AG | Corporate Communications RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany, with five highly specialised maximum- and intermediate-care facilities: Campus Bad Neustadt, Zentralklinik Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM). As a modern, diverse and future-oriented Company, RHÖN-KLINIKUM AG is attractive both as a provider of training and an employer. With over 19,100 employees, the Group offers excellent medical care with a direct tie-in to research and teaching. Each year, we treat a total of 938,000 patients at our hospitals and medical care centres (MVZs) on an outpatient and inpatient basis. Die RHÖN-KLINIKUM AG is a company of the ASKLEPIOS Group. www.rhoen-klinikum-ag.com
06.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a. d. Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate BSX |
| LEI Code: | 529900MVGMIVUDQY9E20 |
| EQS News ID: | 2378340 |
| End of News | EQS News Service |
|
|
2378340 06.08.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 1.360,16 | 1.402,01 | 1.446,09 | 1.463,98 | 1.595,62 | 1.704,72 | 1.700,00 | |
| EBITDA1,2 | 80,23 | 101,16 | 105,65 | 105,88 | 110,77 | 105,94 | 117,00 | |
| EBITDA-Margin3 | 5,90 | 7,22 | 7,31 | 7,23 | 6,94 | 6,22 | 6,88 | |
| EBIT1,4 | 10,60 | 30,52 | 36,11 | 40,40 | 48,15 | 40,94 | 44,00 | |
| EBIT-Margin5 | 0,78 | 2,18 | 2,50 | 2,76 | 3,02 | 2,40 | 2,59 | |
| Net Profit (Loss)1 | 2,46 | 30,23 | 26,94 | 40,17 | 45,21 | 36,28 | 40,00 | |
| Net-Margin6 | 0,18 | 2,16 | 1,86 | 2,74 | 2,83 | 2,13 | 2,35 | |
| Cashflow1,7 | 113,30 | 97,50 | 41,30 | 109,00 | 127,60 | 57,20 | 85,00 | |
| Earnings per share8 | 0,02 | 0,42 | 0,38 | 0,58 | 0,65 | 0,52 | 0,60 | |
| Dividend per share8 | 0,00 | 0,00 | 0,15 | 0,00 | 0,10 | 0,20 | 0,20 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Rhön-Klinikum | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 704230 | DE0007042301 | AG | 964,26 Mio € | 19.06.1991 | Halten | 9F2G86FM+GX |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 21,82 | 27,33 | 0,80 | 28,35 | -0,54 | 16,86 | 0,57 |
|
Dividend '2024 in € |
Dividend '2025 in € |
Dividend '2026e in € |
Div.-Yield '2026e in % |
| 0,10 | 0,20 | 0,20 | 1,39% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.05.2026 | 07.05.2026 | 06.08.2026 | 05.11.2026 | 26.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +4,02% | +10,43% | +13,39% | +24,14% | +476,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.